IFF · International Flavors & Fragrances Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted (Non-GAAP) EPS ex. Amortization non-GAAP | $1.74 | Six Months Ended June 30, 2026 | — |
| Adjusted Operating EBITDA from Continuing Operations non-GAAP | $841M | Six Months Ended June 30, 2026 | — |
| Adjusted Operating EBITDA from Discontinued Operations non-GAAP | $275M | Six Months Ended June 30, 2026 | — |
| Consolidated Adjusted Operating EBITDA Margin non-GAAP | 20.9% | Three Months Ended June 30, 2026 | — |
| Consolidated Segment Adjusted Operating EBITDA Margin non-GAAP | 20.6% | Three Months Ended June 30, 2026 | — |
| Credit Adjusted EBITDA non-GAAP | $2.06B | Twelve Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income $254M
+$187M Interest expense
+$98M Income taxes
+$948M Depreciation and amortization
+$341M Specified items
+$228M Non-cash items
= Credit Adjusted EBITDA $2.06B
|
|||
| Free cash flow non-GAAP | $378M | First Six Months 2026 | — |
| Health & Biosciences adjusted operating EBITDA non-GAAP | $150M | Q2 2026 | — |
|
|
|||
| Health & Biosciences Adjusted Operating EBITDA Margin non-GAAP | 24.7% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Health & Biosciences Segment Adjusted Operating EBITDA non-GAAP | $277M | Six Months Ended June 30, 2026 | — |
| Health & Biosciences Segment Adjusted Operating EBITDA Margin non-GAAP | 24.4% | Six Months Ended June 30, 2026 | — |
| Operating EBITDA non-GAAP | $408M | Q2 2026 | — |
|
|
|||
| Operating EBITDA Margin non-GAAP | 20.9% | Q2 2026 | — |
|
|
|||
| Scent adjusted operating EBITDA non-GAAP | $134M | Q2 2026 | — |
|
|
|||
| Scent Adjusted Operating EBITDA Margin non-GAAP | 20.9% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Scent Segment Adjusted Operating EBITDA non-GAAP | $258M | Six Months Ended June 30, 2026 | — |
| Scent Segment Adjusted Operating EBITDA Margin non-GAAP | 20.3% | Six Months Ended June 30, 2026 | — |
| Segment Adjusted Operating EBITDA non-GAAP | $803M | Six Months Ended June 30, 2026 | — |
| Taste adjusted operating EBITDA non-GAAP | $124M | Q2 2026 | — |
|
|
|||
| Taste Adjusted Operating EBITDA Margin non-GAAP | 20.2% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Taste Segment Adjusted Operating EBITDA non-GAAP | $268M | Six Months Ended June 30, 2026 | — |
| Total IFF Adjusted Operating EBITDA Inclusive of Discontinued Operations non-GAAP | $1.12B | Six Months Ended June 30, 2026 | — |
| Food Ingredients adjusted operating EBITDA non-GAAP | $114M | first quarter 2026 | — |
|
|
|||
| Food Ingredients adjusted operating EBITDA margin non-GAAP | 13.6% | first quarter 2026 | — |
|
|
|||
| Net debt to credit-adjusted EBITDA non-GAAP | 2.5 | first quarter 2026 | — |
| Adjusted operating EBITDA non-GAAP | $2.09B | the full year | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IFF
this stock
International Flavors & Fragrances Inc
|
$21.47B | +25.1% | -5.2% | 76.5 | 6.4% |
|
LIN
Linde PLC
|
$224.91B | +14.3% | +3.0% | 31.5 | 1.2% |
|
AIQUF
L Air Liquide SA /Fi
|
$123.27B | +4.3% | — | — | 0.0% |
|
SHW
Sherwin Williams Co
|
$84.14B | +7.0% | +2.1% | 32.0 | 2.6% |
|
ECL
Ecolab Inc.
|
$78.91B | +7.3% | +2.2% | 37.8 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IFF | +0.1% | +11.0% | +4.4% | +6.4% | +25.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +1.5% | +7.4% | -7.2% | +3.9% | +12.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.